Agreements

* On November 4, 2013, 4SC AG, a discovery and development company of targeted small molecule drugs mainly focusing on cancer and autoimmune diseases, has announced that 4SC Discovery GmbH, Crelux GmbH and AiCuris GmbH & Co. KG have started a drug discovery collaboration to identify and validate novel small molecule compounds targeting pathogen-specific interactions in infectious diseases. Based on the joint integrated drug discovery platform i2c (idea-to-candidate), operated by 4SC Discovery and Crelux, Crelux and 4SC Discovery will discover and optimize small molecule compounds with the goal to deliver high quality drug candidates for a novel anti-infectious therapeutic approach by AiCuris. A virtual screening approach using 4SC\'s proprietary 4SCan(R) method will be performed to identify various inhibitors to the therapeutic target. Compounds identified as potential inhibitors of the respective target will be verified by using both, established assays at AiCuris and the INTRACT in vitro screening systems at Crelux. In the course of the further discovery process, protein structures of verified hits with the target will be solved by i2c to enable rational design and guide the further chemical optimization.